HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Announce 2019 Final Results

Chi-Med to Announce 2019 Final Results

LONDON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT).

A presentation for analysts and investors will be held at 9:00 am GMT (5:00 pm Hong Kong Time) on the same day at Panmure Gordon, One New Change, London, EC4M 9AF, UK. The presentation will be webcast live via the company website at .  The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm GMT on the same day).  

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement.  A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products.  Its Innovation Platform, Hutchison MediPharma, has about 500 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world.  Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market.  For more information, please visit: -med.com.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President
Annie Cheng, Vice President+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson 9 (Mobile)

Xuan Yang, Solebury Trout+1 (415) 971 9412 (Mobile)

  
Media Enquiries 
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson 8 (Mobile)

Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Hong Kong & Asia ex-China– Joseph Chi Lo, Brunswick (Mobile)

 – Zhou Yi, Brunswick (Mobile)

Mainland China – Sam Shen, Edelman 29 (Mobile)

  
Nominated Advisor 
Atholl Tweedie, Panmure Gordon (UK) Limited+44 (20) 7886 2500

 

EN
31/01/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Bi-Weekly: Poised For Strength

The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8% in the first two weeks of Feb 26. InSilico took the lead with a 16.9% share price increase, while CRO leaders WuXi AppTec and WuXi Bio gained 11.7% and 8.1% respectively. Innovent also outperformed its peers with a 9.2% rise. Fuelled by strong innovation, business development momentum, and robust 2025 results, the Chinese healthcare sector is expected to remain resilient in 2026. Maintain OVERWEIGHT.

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Internet Healthcare: Evolving Amid AI Innovation And Poli...

China’s internet healthcare segment is entering a new phase, fuelled by accelerating AI innovation from tech giants and policy support, eg the pilot programme for first-time online consultations. Despite profitability challenges, leading players are leveraging AI ecosystems and innovative strategies to position themselves for sustained long-term growth. We maintain BUY on Ali Health and PAGD. Maintain OVERWEIGHT on the China healthcare sector.

 PRESS RELEASE

HUTCHMED to Announce 2025 Final Results

HUTCHMED to Announce 2025 Final Results HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Bi-Weekly: Stay Focused On Innovation

Since OpenAI’s launch of ChatGPT Health, internet healthcare share prices have fluctuated significantly. In the period 15-29 January, PAGD and Medlive dropped 15.5% and 21.7% respectively, while Ant Group-backed Ali Health remained relatively stable. Many drug innovators retreated 5-10% after an early rally, but AI-driven Insilico surged 18.8%. With robust innovative pipelines, rapid R&D, and growing product offerings, China's healthcare sector is poised to become a key player in the global mark...

Damon Shen ... (+2)
  • Damon Shen
  • Jieqi Liu

China Healthcare: Harnessing R&D Excellence For Global Expansion.

At the recent investor conference, global investors viewed Chinese healthcare companies with increasing interest and optimism. Impressed by their advanced R&D pipelines and swift R&D-to-market execution capabilities, investors recognised Chinese companies’ potential for innovation and growth, particularly as they presented an array of cuttingedge products ready for global markets. This positive perception reflects a growing confidence in China's healthcare sector as a key player on the internati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch